LEADER 01548nam 2200433 a 450 001 9910703374703321 005 20120813081459.0 035 $a(CKB)1000000000708332 035 $a(OCoLC)805928876 035 $a(EXLCZ)991000000000708332 100 $a20120813d1994 ua 0 101 0 $aspa 135 $aurmn||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aClordano$b[electronic resource] 210 1$a[Atlanta, GA] :$cAgencia para Sustancias To?xicas y el Registro de Enfermedades, Divisio?n de Toxicologi?a, Departamento de Salud y Servicios Humanos de los EE.UU., Servicio de Salud Pu?blica,$d[1994] 215 $a1 online resource (7 unnumbered pages) 225 1 $aResumen de salud pu?blica 300 $aTitle from PDF title screen (viewed June 21, 2012). 300 $a"Mayo de 1994." 300 $aSpanish version. 300 $a"CAS# 12789-03-6." 606 $aChlordan$xEnvironmental aspects 606 $aChlordan$xHealth aspects 606 $aChlordan$xPhysiological aspects 606 $aHazardous substances$zUnited States 615 0$aChlordan$xEnvironmental aspects. 615 0$aChlordan$xHealth aspects. 615 0$aChlordan$xPhysiological aspects. 615 0$aHazardous substances 712 02$aUnited States.$bAgency for Toxic Substances and Disease Registry.$bDivision of Toxicology. 801 0$bGPO 801 1$bGPO 906 $aBOOK 912 $a9910703374703321 996 $aClordano$93518030 997 $aUNINA LEADER 03070nam 2200757z- 450 001 9910557494603321 005 20220111 035 $a(CKB)5400000000042885 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/76581 035 $a(oapen)doab76581 035 $a(EXLCZ)995400000000042885 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aNewborn Screening for Pompe Disease 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 online resource (146 p.) 311 08$a3-0365-0580-6 311 08$a3-0365-0581-4 330 $aPompe disease, also known as acid maltase deficiency or acid alpha-glucosidase deficiency, in its most severe form results in a rapidly progressive, neonatal-onset skeletal and cardiomyopathy, leading to early infantile death without treatment. The development of treatment with recombinant enzyme replacement therapy radically transformed the clinical trajectory of those affected, enabling long-term ventilator-free survival with resolution of cardiomyopathy. These positive clinical outcomes resulted in the implementation of newborn screening programs for Pompe disease across the world. This Special Issue highlights some of the experiences of Pompe screening programs worldwide and discusses public policy and ethical issues elicited by presymptomatic screening for Pompe disease. 606 $aTechnology: general issues$2bicssc 610 $aacid ?-glucosidase 610 $aalpha glucosidase 610 $ac.-32-13T& 610 $aCalifornia 610 $across-reactive immunologic material 610 $adiagnosis 610 $adried blood spots 610 $aenzyme replacement therapy 610 $afollow-up 610 $aG 610 $aGAA sequencing 610 $agenotype-phenotype correlation 610 $agt 610 $aimmune modulation therapy 610 $ainfantile onset Pompe disease 610 $ainfantile-onset 610 $ainfantile-onset Pompe disease 610 $alate onset Pompe disease 610 $alate-onset 610 $alysosomal storage diseases 610 $an/a 610 $anew disorders implementation 610 $anewborn screening 610 $anext generation sequencing 610 $apatient perspective 610 $aPompe disease 610 $aPompe disease diagnostics testing 610 $apresymptomatic 610 $apseudodeficiency 610 $atreatment and follow-up 610 $avariant cut-off 615 7$aTechnology: general issues 700 $aHwu$b Wuh-Liang$4edt$01302774 702 $aChien$b Yin-Hsiu$4edt 702 $aWang$b Raymond$4edt 702 $aHwu$b Wuh-Liang$4oth 702 $aChien$b Yin-Hsiu$4oth 702 $aWang$b Raymond$4oth 906 $aBOOK 912 $a9910557494603321 996 $aNewborn Screening for Pompe Disease$93026551 997 $aUNINA